Reckitt Benckiser posts third online video game to entice prospective employees
PARSIPPANY, N.J. — Reckitt Benckiser on Thursday unveiled Turbo RACER, a new free online game and a free mobile racing-game app available on iTunes, as part of the company’s corporate awareness program. The game is designed to metaphorically underscore the essence of working at RB.
Turbo RACER is RB’s third launch in a series of such online games as PoweRBrands and Urban Thrill. With each of these mobile games, RB hopes to further engage its target audience: students and those driven young professionals who are early on in their careers. The successful April launch of Urban Thrill, which is based on the cityscape sport of freerunning, has already been played by more than 490,000 users in the first three months.
RB chose a racing platform for this newest game to help reinforce the company’s rapid-paced corporate culture. "I often describe our culture at RB the same way I would describe a Formula 1 racing car: all engine, all go. Very fast-moving, but no frills and no cruise-control button," stated Andraea Dawson-Shepherd, SVP global corporate communications at RB.
Go to Turbo-Racer.com to download the game.
Endo ends axomadol collaboration with Grunenthal
CHADDS FORD, Pa. — Endo Pharmaceuticals has ended its research program and collaboration with Grunenthal.
The announcement comes shortly after the companies revealed their mid-stage clinical trial results for axomadol — designed to treat chronic low back pain — did not meet the predetermined endpoint.
Endo licensed exclusive rights to develop and market axomadol in the United States and Canada from Grunenthal in February 2009.
"As a leader in the field of pain management, Endo remains committed to the development and commercialization of pain therapeutics," Endo Pharmaceuticals EVP research and development Ivan Gergel said. "We have appreciated the opportunity to collaborate with Grunenthal on this program and they have been an excellent partner."
Sun Pharma receives FDA OK for finasteride
MUMBAI, India — Generic drug maker Sun Pharmaceutical Industries has received regulatory approval for a drug designed to treat an enlarged prostate.
According to the Food and Drug Administration’s website, Sun Pharma’s finasteride tablets in the 5-mg strength were approved on Aug. 16.
Finasteride is the generic equivalent of Proscar and Propecia, which are made by Merck.